Search or ask a question

Can I donate plasma if I take diclofenac?

Pharmacokinetics

Volume of distribution

Absorption (skin)

Diclofenac Sodium

Answers from top 6 papers

PDF

Open Access

More filters

Papers (6)	Insight
Journal Article•DOI Effect of sodium diclofenac on the bioavailability of amoxicillin Cristiane de Cássia Bergamaschi, Rogério Heládio Lopes Motta, Gilson Cesar Nobre Franco, Karina Cogo, Michele Franz Montan, Gláucia Maria Bovi Ambrosano, Pedro Luiz Rosalen, Fernando de Sá Del Fiol, Francisco Carlos Groppo - Show less +8 more 01 May 2006-International Journal of Antimicrobial Agents 24 Citations	In conclusion, sodium diclofenac can significantly reduce the bioavailability of amoxicillin.
Open access•Journal Article•DOI Effect of diclofenac on renal function and prostacyclin generation after surgery I. Power, A.D. Cumming, G.C. Pugh - Show less +2 more 01 Nov 1992-BJA: British Journal of Anaesthesia 41 Citations	Urine flow rate and blood potassium concentration should be monitored if diclofenac is used after major surgery.
Open access•Journal Article•DOI Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass José Otávio Costa Auler, Eloisa Bonetti Espada, E. Crivelli, T. B. G. Quintavalle, A. Kurata, Noedir Antônio Groppo Stolf, Adriana Machado Issy, O. E. D. Paschoa, M. Danhof, D. D. Breimer, Dalton de Alencar Fischer Chamone, Silvia Regina Cavani Jorge Santos - Show less +11 more 01 Mar 1997-Brazilian Journal of Medical and Biological Research 9 Citations	In conclusion, the extent of plasma diclofenac protein binding was influenced by CPB with clinically relevant kinetic-dynamic consequences.
Journal Article•DOI Bioequivalence study of low-dose diclofenac potassium tablet formulations. Hinz B, Hug Am, Fotopoulos G, Gold Ms - Show less +3 more 01 Oct 2009 6 Citations	Plasma time courses of diclofenac were similar for the tested formulations.
Journal Article•DOI The disposition of diclofenac in camels after intravenous administration. I.A. Wasfi, Mussarat Hussain, M. Elghazali, N. A. Alkatheeri, A.A. Abdel Hadi - Show less +4 more 01 Nov 2003-Veterinary Journal 10 Citations	Both diclofenac and hydroxy diclofenac, appear to be the main elimination route for diclofenac when administered i.v.
Journal Article•DOI Diclofenac metabolic profile following in vitro percutaneous absorption through viable human skin. Hanafi Tanojo, Ronald C. Wester, J Z Shainhouse, Howard I. Maibach - Show less +3 more 01 Oct 1999-European Journal of Drug Metabolism and Pharmacokinetics 17 Citations	Hence, with topical application to human skinin vivo, diclofenac will be delivered with minimal, if any, metabolism.

My columns

Related Questions

Can I donate plasma if I take cyclobenzaprine?5 answers

Can I donate plasma if I take venlafaxine?5 answers

Can I donate plasma if I'm taking clindamycin?6 answers

Can I donate plasma while on ciprofloxacin?6 answers

Can I donate plasma while taking naltrexone?7 answers

Can you donate plasma if you use opiates?6 answers

See what other people are reading

What is a different simplex lattice design?

A variety of simplex lattice designs have been utilized in different fields for optimization purposes. For instance, a modified Scheffe’s simplex lattice design method was employed to determine optimal compositions of ceramic materials for gas purification equipment. In another study, simplex lattice design was applied to predict drug release patterns from extended release diclofenac sodium tablets. Furthermore, the Simplex Lattice Design method was used to optimize the formulation of aloe vera extract liquid soap, considering parameters like viscosity, specific gravity, foam resistance, and pH. Additionally, Simplex Lattice Design models were developed to assess the suitability of run-off sand for concrete production and predict the Modulus of Rupture of Concrete beams. Lastly, simplex lattice design was employed to optimize the formulation of andrographolide self-nanoemulsifying drug delivery systems, focusing on characteristics like emulsification time, droplet size, and drug content.How equisetum diffusum is used in herbal medicines?

Equisetum diffusum, commonly known as 'Himalayan horsetail,' is utilized in herbal medicine due to its anti-inflammatory properties. This plant species has been traditionally employed by various tribal communities in India for treating back pain, bone-related issues, and arthritis. The whole plant methanolic extract of Equisetum diffusum has been found to inhibit protein denaturation, erythrocyte membrane lyses, and reduce paw-edema in experimental animal models, showcasing its anti-inflammatory effects. Additionally, the presence of phyto-compounds like Stigmasta-3,5-dien-7-one and 4H-Pyran-4-one, 2,3-dihydro-3,5-dihydroxy-6-methyl in the extract contributes to its anti-inflammatory properties. These findings support the potential of Equisetum diffusum in herbal medicine for managing inflammation-related complications, hinting at its future role in drug development.What affect drug distribution volume?

Drug distribution volume is influenced by various factors such as physiological processes like pregnancy and growth, chemical properties of the drug, and tumor biological properties. Physiologically, pregnancy and growth lead to changes in distribution volume and clearance due to fluid expansion and organ perfusion. Chemical properties like lipophilicity and the presence of basic functional groups impact volume of distribution, with basic molecules typically exhibiting higher volumes of distribution. In tumors, drug distribution is dependent on tumor volume, vasculature, and porosity, affecting the concentration and effectiveness of anticancer treatments. Understanding these factors is crucial in optimizing drug dosing regimens and enhancing treatment outcomes.What affects the Vd value of a drug? Can edema affect the Vd value? Explain!?

The volume of distribution (Vd) of a drug is influenced by various factors such as plasma protein binding, patient's weight, age, and disease conditions like renal or liver disease. Changes in Vd can impact the therapeutic or toxic levels of a drug in the body. For instance, drugs with reduced plasma binding in patients with liver or kidney disease may exhibit an increased Vd. Edema can also affect Vd values, as seen in a study on prostate brachytherapy where V 100 and D 90 parameters increased during the first 30-60 days post-implant due to edema, indicating a proportional relationship between edema magnitude and Vd changes. Therefore, disease-induced alterations and conditions like edema can significantly impact the Vd of a drug.What is the optimal dose time for DIPAS (Diphenhydramine) to achieve maximum effectiveness?

The optimal dose time for Diphenhydramine (DIPAS) to achieve maximum effectiveness depends on the therapeutic objective, the medication, and the blood pressure (BP) profile. Studies have shown that chrono-pharmacological optimization significantly reduces long-term cardiovascular risk if a BP dipper pattern is maintained. Diphenhydramine has been found to be effective as an antitussive agent, with a 25 mg dose showing effectiveness as early as 15 minutes post-ingestion and maintaining efficacy over a 4-hour period. Additionally, Diphenhydramine pharmacokinetics in children showed that a weight-age dosing schedule with an 8-fold range of doses achieved increased Cmax and AUC across age groups, with no maturation-related change in clearance after allometric scaling. Therefore, personalized chrono-pharmacological recommendations for Diphenhydramine dosing should consider the individual's BP pattern, age, and the desired therapeutic outcome.What is the current status of clinical trials for dolastatin 10 in the treatment of cancer?

Clinical trials for dolastatin 10 in cancer treatment have shown promising results. Dolastatin 10 and its derivatives have demonstrated potent antitumor activity against various cancer cell lines, including leukemia, lung cancer, and prostate cancer. Novel cyclopeptide derivatives of dolastatin 10 have been developed, showing good inhibitory effects on tumor cells, especially colon cancer cells. Additionally, modifications like phosphate or quinoline have enhanced the delivery of dolastatin analogues to cancer sites, improving their efficacy in inhibiting cancer cell growth. These advancements highlight the potential of dolastatin 10 as a valuable compound in cancer therapy, with ongoing clinical trials focusing on its efficacy and safety in treating different types of cancers, such as non-small cell lung cancer.What is the effect of apixaban on kidney function in patients with atrial fibrillation?

Apixaban has shown varying effects on kidney function in patients with atrial fibrillation (AF). Studies have highlighted different aspects: - The RENAL-AF trial compared apixaban to warfarin in AF patients on hemodialysis, showing no significant difference in bleeding rates or stroke prevention. - In contrast, the CALLIPER study found that rivaroxaban 15 mg daily was associated with a 47% reduced risk of worsening kidney function compared to warfarin in AF patients with moderate-to-severe chronic kidney disease. - Edoxaban, another anticoagulant, demonstrated superiority to warfarin in terms of net clinical outcomes in AF patients with varying levels of creatinine clearance, suggesting potential benefits for patients with chronic kidney disease. Overall, while apixaban's impact on kidney function in AF patients remains inconclusive, other anticoagulants like rivaroxaban and edoxaban show promising results in specific subgroups.What factor that influence volume of distribution drug?

The volume of distribution (Vd) of a drug is influenced by various factors. Physiological properties of the body and physiochemical properties of the drug play crucial roles in determining Vd. Lipid partitioning and protein binding are key factors that collectively determine drug distribution. Additionally, the molecular characteristics of the drug, such as being basic or neutral, can impact Vd, with basic molecules tending to exhibit higher Vd compared to neutral molecules. Alterations in drug transporter function, whether due to drug-drug interactions, genetic polymorphisms, or knockout animals, can also significantly affect Vd, leading to changes in drug effect, toxicity, and half-life independent of clearance changes. Strategies to increase Vd include enhancing lipophilicity and incorporating basic functional groups without increasing metabolic clearance.Is diclofenac a safe choice for patients with gastric ulcers?

Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), poses risks for patients with gastric ulcers. Prolonged use of diclofenac can lead to bleeding and ulcers in the stomach or intestine. Inappropriate use of diclofenac patches has been linked to peptic ulcer bleeding. However, studies suggest that the risk of NSAID-induced peptic ulcers can be reduced by using proton pump inhibitors, misoprostol, and histamine-2 receptor antagonists alongside NSAIDs. Additionally, the protective effect of pirfenidone, an alternative treatment, has shown promise in reducing gastric damage caused by diclofenac. Therefore, while diclofenac can be effective for pain relief, caution is advised in patients with gastric ulcers, and alternative treatments or additional protective measures may be considered to mitigate the risk of adverse effects.What is fentanyl's pharmacokinetic distribution to organs?

Fentanyl's pharmacokinetic distribution to organs involves a complex interplay of factors. Studies have shown that fentanyl exhibits extensive extravascular distribution, with a total apparent volume of distribution (Vss) ranging from 300 to 400 1/70 kg. The drug's distribution to specific organs like the brain, lung, and muscle has been modeled using physiologically-based population recirculatory models, highlighting the concentration gradients across these organs. Additionally, in parturient women receiving fentanyl during cesarean sections, rapid passage of fentanyl from the epidural space to maternal blood and significant transplacental transfer have been observed, with a fetal/maternal plasma ratio of approximately 0.892. These findings underscore the importance of understanding fentanyl's distribution dynamics in different physiological contexts and its implications for maternal-fetal exposure.How long should imatinib be taken for GIST?

The duration of imatinib treatment for gastrointestinal stromal tumors (GIST) varies depending on the clinical scenario, including whether the treatment is neoadjuvant, adjuvant, or for metastatic disease. For neoadjuvant therapy, a study found the optimal duration to be around 6.1 months on average, with the time to maximal tumor shrinkage varying by tumor location. In the adjuvant setting, particularly for high-risk GISTs, treatment duration can significantly impact progression-free survival (PFS), with regular postoperative imatinib therapy showing longer PFS compared to irregular or observation-only approaches. However, the optimal dose in the adjuvant setting, especially for KIT exon 9-mutated GISTs, remains a subject of investigation, with some evidence suggesting that 400 mg daily may be beneficial. For patients with metastatic GIST, life-long treatment with tyrosine kinase inhibitors (TKIs) like imatinib is generally recommended. However, there are instances where highly selected patients with oligo-metastatic disease may safely discontinue imatinib after long-term treatment and remain in durable complete remission. This suggests that, under certain conditions, discontinuation of imatinib might be feasible, although this requires careful patient selection and monitoring. The effectiveness of imatinib can be influenced by pharmacokinetic factors, such as a significant decrease in systemic exposure to the drug after long-term treatment, which underscores the importance of monitoring and potentially adjusting the dose over time. Additionally, real-life data indicate that outcomes for patients treated with imatinib have improved over time, suggesting that with current management strategies, patients may experience better results than those reported in earlier trials. In summary, the duration of imatinib therapy for GIST should be tailored to the individual patient's disease status and response to treatment, with considerations for the specific setting of therapy (neoadjuvant, adjuvant, or metastatic), the presence of specific mutations, and the patient's tolerance to the drug.